A Clinical Trial of STP0404 in Adults With HIV-1 Infection

ST Pharma

Status and phase: Enrolling; Phase 2

Conditions: HIV-1-infection

Treatments: Drug: High-dose STP0404 (Pirmitegravir); Drug: Low-dose STP0404 (Pirmitegravir); Drug: Medium-dose STP0404 (Pirmitegravir); Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT05869643

STP-POC-001

Details and patient eligibility

About

The purpose of this study is to evaluate the antiviral effect, safety, tolerability, and pharmacokinetics of STP0404 in adult participants living with Human Immunodeficiency Virus Type 1 (HIV-1) infection.

Enrollment: 36 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Have a confirmed HIV-1 infection in the documented medical record or at screening.
• Have never received any ARTs (i.e., treatment-naïve) before screening or only received one ARV regimen (2 or 3 drugs) at least 12 weeks before screening and/or received any monotherapy ≤10 days in a clinical trial setting at least 12 weeks before screening. Participants with a documented history of PrEP and/or PEP therapy but discontinued at least 8 weeks prior to screening are also eligible for inclusion.
• Have a CD4+ cell count ≥200 cells/mm3 at screening.

Exclusion criteria

• Have a hepatitis B surface antigen or positive hepatitis C virus antibody at screening. An HCV confirmation (HCV RNA test) will be performed at a central laboratory if the HCV antibodies screening result is positive. If the HCV RNA test result is negative, the participant will be eligible.
• Have a positive drug screen for amphetamines, barbiturates, cocaine, opiates, benzodiazepines, heroin, or phencyclidine. However, if in the opinion of the investigator, positive drug screen results may be due to prescription medication for therapeutic purposes (e.g., prescription Adderall for ADHD), eligibility decision shall rely on the investigator's medical judgment and should be documented.
• Have a history of regular alcohol consumption, defined as an average weekly intake of >14 drinks (males) or >7 drinks (females), within 6 months of screening and/or has positive alcohol screen at screening and baseline.
• Have received the following treatments as PrEP or PEP (≥1 dose) prior to screening: monoclonal antibodies, HIV-1 maturation inhibitors, and long-acting INSTIs (such as cabotegravir).
• Pregnant or lactating females.
• Have a history of clinically relevant pancreatitis or hepatitis within the previous 6 months.
• Participant received any allosteric HIV-1 integrase inhibitor (ALLINI, ≥1 dose) and/or received any long-acting ARVs (marketed or investigational, ≥1 dose) prior to screening.
• Have previously failed an INSTIs-containing regimen.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

36 participants in 6 patient groups, including a placebo group

Cohort 1 STP0404

Experimental group

Treatment:

Drug: Low-dose STP0404 (Pirmitegravir)

Cohort 1

Placebo Comparator group

Treatment:

Drug: Placebo

Cohort 2 STP0404

Experimental group

Treatment:

Drug: Medium-dose STP0404 (Pirmitegravir)

Cohort 2

Placebo Comparator group

Treatment:

Drug: Placebo

Cohort 3 STP0404

Experimental group

Treatment:

Drug: High-dose STP0404 (Pirmitegravir)

Cohort 3

Placebo Comparator group

Treatment:

Drug: Placebo